Barrow Neurological Institute Selects Cubresa’s BrainPET System to Support Neurological Research Activities

WINNIPEG, Manitoba--(BUSINESS WIRE)--Barrow Neurological Institute, the world’s largest neurological disease treatment and research institution, in conjunction with Arizona State University (ASU), have selected Cubresa’s BrainPET system to add to their suite of imaging tools.

A joint acquisition between Barrow Neurological Institute and ASU, the BrainPET scanner will reside at Barrow and will be used to support neurological research studies, adding simultaneous PET/MR imaging capability to their respective research programs.

“We were incredibly excited to learn about the capabilities of the Cubresa BrainPET”, remarked Dr. Chad Quarles, Professor and Chair, Division of Neuroimaging Research, and the Director of the Barrow Neuroimaging Innovation Center at the Barrow Neurological Institute. “The integration of the BrainPET into our existing MRI system enables our researchers to simultaneously interrogate anatomic, physiologic and molecular features across a range of neurologic disorders, and we gain these features without having to purchase and create facilities for a new dedicated PET/MRI system.”

“We are extremely pleased that Barrow and ASU have joined Cubresa’s Foundational Client Program for our BrainPET system”, said James Schellenberg, Ph.D., Cubresa’s Founder and CEO. “We look forward to supporting their research activities through our technology and are excited to see the impact the BrainPET system will have on their respective research initiatives.”

Cubresa’s Foundational Client Program is designed for world-leading, innovative brain research institutions who are seeking to enhance their brain-focused research activities with the addition of a novel BrainPET system, enabling simultaneous PET/MR imaging.

About BrainPET

BrainPET is an investigational PET insert dedicated to the human brain imaging marketplace. It is intended to retrofit into installed 1.5T, 3T and 7T MRI systems, and will be useful for those clinical sites that want the advantages of simultaneous PET-MR imaging. The BrainPET insert is being developed to enhance the detection, diagnosis, and treatment of neurological diseases including Alzheimer’s and other dementias as well as brain cancers, epilepsy surgical planning and movement disorders. BrainPET is an investigational device and is not available for commercial sale.

About Cubresa Inc.

Cubresa, based in Winnipeg Canada, is a world leader in the design and development of preclinical and clinical PET inserts for MRI. Cubresa products are being developed to enable researchers at leading universities, hospitals and pharmaceutical companies to visualize and measure biochemical processes at the molecular level. www.cubresa.com